Phase 2 data focused on metabolic outcomes, and GLP-1 receptor activity in mood-regulating brain regions remains a theoretical rather than proven concern
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the First-in-Class GLP-1 and Amylin Receptor Agonist, Amycretin: A First-in-Human, Phase 1, Double-Blind, Randomised, Placebo-Controlled Trial
Additionally, there are certain classes of medications that hinder healing, including immunosuppressants, corticosteroids, non-steroidal anti-inflammatory drugs (NSAIDs), and anticoagulants
The guys who benefit most from adding peptides to their TRT are the ones who've already optimized the basics, have specific goals these compounds can address, and work with providers who separate science from sales pitch
Journal of Applied Physiology (Bethesda, Md.: 1985) , 110 (3), 774780